Year-End Report April 2024 - March 2025
Regulatory
Sales and operating profit growth, significant product acquisition completed, 11 new products, first deal outside Europe and graduation year passed
Press Releases
Invitation to presentation in connection with EQL Pharma's year-end report, fourth quarter, 2024/25
EQL Pharma AB (publ) will publish its year-end report for the fourth quarter, 2024/25, on Thursday, May 8[th], before stock markets open.
EQL Pharma signs a distribution agreement with a large distributor in the GCC countries for Mellozzan (melatonin)
EQL has entered into an exclusive distribution agreement with Pharmalink for its product Mellozzan (melatonin) for the GCC (Gulf Cooperation Council) region comprising of United Arab Emirates, Saud...
New financial targets for the period 2024/25 – 2028/29
Regulatory
EQL will shortly conclude the 5-year plan for 2020/21 – 2024/25. Thus, the Company today 7 March presents new financial targets for the period 2024/25 – 2028/29.
Nomination committee for the 2025 Annual General Meeting
Regulatory
According to the resolution of the 2024 Annual General Meeting, the Nomination Committee shall be convened by the Chairman of the Board and consist of a representative of each of the three largest ...